Humanis

What Humanis does

Humanis (legal name: Humanis Sağlık Anonim Şirketi) is a Turkey-based pharmaceutical and healthcare company operating as a subsidiary of Saya Holding, a diversified conglomerate. Founded in 2010 and headquartered at Maslak Link Plaza in Istanbul's Sarıyer district, the company develops, manufactures, and commercializes pharmaceutical products across multiple therapeutic areas — including pulmonary vascular diseases, psychiatry, and neurology — alongside a consumer health (OTC) product line. Humanis employs between 1,001 and 5,000 people and maintains both domestic distribution through Turkish pharmacy networks and healthcare institutions and a dedicated International Markets (Uluslararası Pazarlar) unit for export operations.

The company's product portfolio spans three categories. Its prescription pharmaceutical business targets specialized therapeutic areas, with a documented first-in-Turkey introduction of a Parkinson's disease-related psychosis treatment launched after the United States approval in 2024. Humanis also distributes consumer health (OTC) products through retail and pharmacy channels. In May 2025 the company launched PAHCase, a digital case platform for physicians working in pulmonary vascular diseases that offers case simulations close to real clinical practice and enables multidisciplinary specialist evaluation through closed council structures. The company positions its core values around human-centered healthcare, innovation, and diversity, and maintains manufacturing and R&D capabilities alongside its commercial operations.

Humanis operates a sales-led go-to-market model targeting healthcare professionals and institutions, supplemented by event-driven promotion at medical conferences such as the 8th Pulmonary Vascular Diseases Meeting (May 21–24, 2025). Revenue is generated primarily through pharmaceutical product sales across domestic pharmacy distribution and export markets (modeled as one-time licensing-style transactions), with a newer recurring-revenue component via the PAHCase digital platform. The company is privately held with no disclosed financial data on revenue, pricing, or profitability, and strategic and financial backing flows through its parent Saya Holding.

Name

Humanis

Legal name

Humanis Sağlık Anonim Şirketi

Website

https://humanis.life

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Humanis is a Turkey-based pharmaceutical subsidiary of Saya Holding that develops, manufactures, and distributes prescription medicines across pulmonary vascular, psychiatry, and neurology therapeutic areas, alongside consumer health products and the PAHCase digital physician platform.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

akta.pro secondary industries

OTC & Consumer Health Distributors (HLAIAJAC), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Rare disease pharmaceuticals
• Pulmonary hypertension treatments
• Consumer health products
• Digital case platform
• Specialty pharmaceuticals

Headquarters

HQ city

Maslak

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Products: Humanis develops and commercializes pharmaceutical products across multiple therapeutic areas including pulmoner vascular diseases, psychiatry, and neurology. The company operates in consumer health and exports to international markets.
2. Consumer Health Products: Products targeted at consumer health markets distributed through pharmacies and healthcare retailers.
3. Digital Health Solutions: Digital platforms providing case simulation and expert consultation services for healthcare professionals, supporting scientific sharing and experience transfer.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Humanis manufactures and distributes pharmaceutical products for the treatment of rare and specialty diseases, with focus on pulmonary vascular diseases, psychiatry, and neurology, including the first-in-Turkey Parkinson's disease psychosis treatment. The company also markets a portfolio of consumer health (OTC) products and operates the PAHCase digital case platform for pulmonary vascular disease specialists. As a subsidiary of Saya Holding, it combines pharmaceutical manufacturing and distribution with digital health solutions targeting healthcare professionals.

Product overview

Humanis is a pharmaceutical and healthcare company operating under Saya Holding, organized as a single unified product portfolio. The core offerings span three key areas: (1) PAHCase — a digital case platform for pulmonary vascular disease physicians enabling case simulations and multidisciplinary council evaluations; (2) prescription pharmaceutical products covering therapeutic areas including psychiatry and pulmonary vascular diseases; and (3) consumer health (OTC) products. The company also brought an innovative Parkinson's disease psychosis treatment to Turkey, the first such introduction in the country after the United States. Humanis maintains manufacturing and R&D capabilities alongside its international market operations.

Differentiator

Problem solved

Functional benefit

Brands

• PAHCase: Digital platform for physicians working in pulmonary vascular diseases, offering case simulations close to real clinical practice and enabling multidisciplinary communication in pulmonary hypertension.

Products and services

• PAHCase Digital Case Platform A digital case platform for physicians working in pulmonary vascular diseases, offering case simulations close to real clinical practice and enabling multidisciplinary specialist consultations through a closed council structure to support scientific sharing and experience transfer.
• Humanis Pharmaceutical Products Portfolio Prescription pharmaceutical products across multiple therapeutic areas including pulmonary vascular diseases, psychiatry, and neurology, distributed through pharmacy networks and healthcare institutions.
• Tuketici Sagligi (Consumer Health) Over-the-counter consumer health products focused on general wellness and self-care needs, distributed through pharmacies and healthcare retailers.
• Parkinson's Disease Psychosis Treatment A pharmaceutical treatment for psychosis associated with Parkinson's disease (hallucinations and delusions), introduced in Turkey for the first time following US availability.

Quantifiable outcome

• First market entry for Parkinson psychosis treatment in Turkey following US approval

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Almirall: European specialty pharma focused on dermatology and rare/specialty conditions, with growing CNS activities. Comparable as a specialty pharma competitor operating across smaller European-adjacent markets with a similar mindset of focused therapeutic differentiation.
• Hikma Pharmaceuticals: MENA-focused pharmaceutical company with branded, generic, and consumer health operations. Comparable as a regional pharma operator serving emerging markets through distribution channels similar to Humanis's pharmacy/institution model.
• Ipsen: European specialty pharma with neurology and rare disease franchises. Comparable as a specialty-focused pharma that commercializes differentiated treatments in smaller patient populations, similar to Humanis's neurology and pulmonary vascular focus.
• Recordati: Italian specialty pharmaceutical company with strong presence in cardiovascular and rare disease areas. Comparable as a specialty pharma operator with similar therapy focus (e.g., pulmonary vascular) and a track record of in-licensing and launching niche products in new geographies.

Others

• Veeva Systems: Provider of digital platforms serving the pharmaceutical industry, including physician engagement and commercial operations software. Relevant adjacency for Humanis's PAHCase digital physician engagement platform and digital health strategy.

Regional players

• Sanovel İlaç: Turkish pharmaceutical company with diversified Rx and OTC operations. Closely comparable as a domestic pharma competitor across therapeutic areas and consumer health categories.
• Nobel İlaç: Turkish pharmaceutical manufacturer with broad Rx and consumer health portfolio. Direct comparable as a domestic pharma peer competing in pharmacy and hospital channels across multiple therapeutic areas.
• Deva Holding: Turkish holding with a strong pharmaceutical manufacturing arm covering generics, specialty, and OTC products. Comparable as a Turkish pharma group operating in similar distribution channels and therapeutic segments.
• Abdi İbrahim: Turkey's largest domestic pharmaceutical manufacturer with a diversified Rx and consumer health portfolio. Directly comparable as a Turkish-based pharma company serving similar hospital/pharmacy distribution channels and competing across overlapping therapeutic areas.
• Eczacıbaşı İlaç (EIP Eczacıbaşı): Turkish pharmaceutical subsidiary of the Eczacıbaşı conglomerate, offering Rx and consumer health products. Highly comparable business model as another diversified pharma operating company within a larger Turkish industrial holding group.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/humanis_life
• Facebookfacebook.com/humanis.life
• LinkedInlinkedin.com/company/humanis-healthcare

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Humanis